|21.47||-0.3700||-1.69%||Vol 166.53K||1Y Perf -37.97%|
|Apr 13th, 2021 14:23 DELAYED|
|- -%||- -|
|Target Price||46.78||Analyst Rating||Strong Buy 1.33|
|Potential %||117.58||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||1.03B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||13.19||Earnings Date||5th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-0.80|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||295.43K|
|Avg. Monthly Volume||424.26K|
|Avg. Quarterly Volume||458.03K|
Constellation Pharmaceuticals Inc. (NASDAQ: CNST) stock closed at 21.84 per share at the end of the most recent trading day (a -2.93% change compared to the prior day closing price) with a volume of 408.50K shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Constellation Pharmaceuticals Inc. CEO is Jigar Raythatha.
The one-year performance of Constellation Pharmaceuticals Inc. stock is -37.97%, while year-to-date (YTD) performance is -24.17%. CNST stock has a five-year performance of %. Its 52-week range is between 17 and 50.9, which gives CNST stock a 52-week price range ratio of 13.19%
Constellation Pharmaceuticals Inc. currently has a PE ratio of -8.10, a price-to-book (PB) ratio of 2.66, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.05%, a ROC of -39.56% and a ROE of -33.77%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Constellation Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.80 for the next earnings report. Constellation Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Constellation Pharmaceuticals Inc. is Strong Buy (1.33), with a target price of $46.78, which is +117.58% compared to the current price. The earnings rating for Constellation Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Constellation Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Constellation Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.40, ATR14 : 2.45, CCI20 : -97.05, Chaikin Money Flow : -0.29, MACD : -2.30, Money Flow Index : 40.84, ROC : -6.75, RSI : 38.00, STOCH (14,3) : 5.16, STOCH RSI : 0.81, UO : 29.48, Williams %R : -94.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Constellation Pharmaceuticals Inc. in the last 12-months were: Adrian Senderowicz (Option Excercise at a value of $51 557), Adrian Senderowicz (Sold 9 357 shares of value $469 488 ), Emma Reeve (Option Excercise at a value of $422 654), Emma Reeve (Sold 48 877 shares of value $2 162 876 ), James E. Audia (Sold 13 600 shares of value $644 221 ), Jigar Raythatha (Option Excercise at a value of $50 885), Jigar Raythatha (Sold 9 235 shares of value $463 281 ), Karen Valentine (Option Excercise at a value of $464 740), Karen Valentine (Sold 41 000 shares of value $1 502 355 ), Mark A. Goldsmith (Option Excercise at a value of $78 005), Mark A. Goldsmith (Sold 23 353 shares of value $1 015 661 ), Patrick Trojer (Option Excercise at a value of $70 385), Patrick Trojer (Sold 10 000 shares of value $451 553 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.